Skip to main content

Novartis unit Sandoz set to start trading after completing spinoff

Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.